Joseph A. Sparano, MD Email Joseph Sparano
- SENIOR FACULTY (PENDING) | Medicine, Hematology and Medical Oncology
- Hospital Affiliation
- The Mount Sinai Hospital
- Dubin Breast Center 212-241-3300 212-241-3300
Joseph A. Sparano, MD, FACP, an internationally-recognized expert in the management of breast cancer and HIV-associated malignancies, is Chief of the Division of Hematology and Medical Oncology for the Mount Sinai Health System and Deputy Director of The Tisch Cancer Institute (TCI). He holds the Ezra M. Greenspan MD Professorship in Clinical Cancer Therapeutics.
Dr. Sparano joined Mount Sinai in 2021 following a distinguished 33-year career at the Albert Einstein College of Medicine and Montefiore Medical Center, where he was Professor of Medicine and Obstetrics, Gynecology & Women’s Health, Associate Chairman for Clinical Research in the Department of Oncology, and Associate Director for Clinical Research at the Albert Einstein Cancer Center.
Dr. Sparano led a breakthrough clinical trial in breast cancer research, the Trial Assigning Individualized Options for Treatment (Rx), known as TAILORx—the first and largest National Cancer Institute (NCI) precision medicine trial. It integrated the 21-gene expression assay (Recurrence Score [RS]) into clinical decision making for adjuvant therapy of early stage ER-positive, HER2 negative breast cancer. The trial led to changes in treatment guidelines from both the American Society of Clinical Oncology and the National Comprehensive Cancer Network. TAILORx results were published in the New England Journal of Medicine in 2015, 2018, and 2019. Dr. Sparano also led an effort to develop and validate a new tool integrating clinical and genomic information to guide adjuvant therapy for breast cancer, called RS Clin, which became freely available for widespread clinical use after publication in the Journal of Clinical Oncology in 2021. Evidence generated from another trial that he led which evaluated the role of taxane therapy in early breast cancer, published in the New England Journal of Medicine in 2008, has also had an important and enduring impact on standard clinical practice guidelines.
Dr. Sparano has conducted impactful studies aimed at improving the outcomes of HIV‐positive patients with cancer, including research on novel approaches for treating non‐Hodgkin lymphoma and anal cancer in individuals with HIV. He has also focused his research on improving racial disparities in cancer care and on cancer metastasis. Dr. Sparano’s research over the years has been funded by the NCI as well as the Breast Cancer Research Foundation, Susan G. Komen Foundation, and V Foundation.
Dr. Sparano is Chair and Principal Investigator of the AIDS Malignancy Consortium, a network of clinical trial sites in the U.S., Africa, and Latin America. He serves as Deputy Chair of the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) Cancer Research Group, and is a member of the Board of Managers of the PreECOG Research Foundation and the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Steering Committee.
Dr. Sparano is a recipient of some of the most prestigious awards in the field of medical oncology, including the ECOG Young Investigator Award, the Charles Moertel Award and Lecture by the Alliance for Cancer Clinical Trials, the American Association for Cancer Research William L. McGuire Award and Lecture, and the American Society of Clinical Oncology Gianni Bonadonna Award and Lecture.
American Board of Internal Medicine
MD, New York Medical College
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Sparano during 2020 and/or 2021. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- C Stone
- Celgene Corporation
- Daiichi-Sankyo Co., Ltd.
- EPIC Sciences
- Eisai Inc.
- F. Hoffman-La Roche Ltd.
- Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.